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Palliative primary tumor resection 
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with metastatic colorectal cancer and low 
circulating levels of dehydrogenase 
and carcinoembryonic antigen
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Abstract 
Background: It remains controversial whether palliative primary tumor resection (PPTR) can provide survival benefits 
to the patients with metastatic colorectal cancer (mCRC) who have unresectable metastases. The aim of this study 
was to evaluate whether PPTR could improve the survival of patients with mCRC.
Methods: We conducted a retrospective study on consecutive mCRC patients with unresectable metastases who 
were diagnosed at Sun Yat‑sen University Cancer Center in Guangzhou, Guangdong, China, between January 2005 
and December 2012. Overall survival (OS) and progression‑free survival (PFS) after first‑line chemotherapy failure were 
compared between the PPTR and non‑PPTR patient groups.
Results: A total of 387 patients were identified, including 254 who underwent PPTR and 133 who did not. The 
median OS of the PPTR and non‑PPTR groups was 20.8 and 14.8 months (P < 0.001), respectively. The median PFS after 
first‑line chemotherapy was 7.3 and 4.8 months (P < 0.001) in the PPTR and non‑PPTR groups, respectively. A larger 
proportion of patients in the PPTR group (219 of 254, 86.2%) showed local progression compared with that of patients 
in the non‑PPTR group (95 of 133, 71.4%; P < 0.001). Only patients with normal lactate dehydrogenase (LDH) levels 
and with carcinoembryonic antigen (CEA) levels <70 ng/mL benefited from PPTR (median OS, 22.2 months for the 
PPTR group and 16.2 months for the non‑PPTR group; P < 0.001).
Conclusions: For mCRC patients with unresectable metastases, PPTR can improve OS and PFS after first‑line chemo‑
therapy and decrease the incidence of new organ involvement. However, PPTR should be recommended only for 
patients with normal LDH levels and with CEA levels <70 ng/mL.
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Background
Approximately 25% of patients with colorectal cancer 
present with synchronous metastases at the time of diag-
nosis [1, 2]. Although curative surgery, including eradi-
cation of both the primary cancer and the metastatic 
lesions, can be successful in patients with limited metas-
tasis, most patients remain incurable owing to unresect-
able metastases [3]. For such patients, both the National 
Comprehensive Cancer Network and the European Soci-
ety for Medical Oncology recommend chemotherapy 
without primary cancer resection except in cases of intes-
tinal perforation, intestinal obstruction, or other emer-
gencies [4]. However, increasing evidence indicates that 
palliative primary tumor resection (PPTR) plus chemo-
therapy could extend patients’ survival [5–7], as shown in 
Table 1, which challenges these recommendations.
The specific benefits of PPTR remain undefined, 
because all the published studies are retrospective and 
have reported contradictory results; no randomized 
controlled studies have been reported. In addition, in a 
previous study, the effect of palliative surgery on survival 
was confounded by the differential use of chemotherapy 
drugs [8]. Furthermore, some studies did not provide 
details about the chemotherapy used [9–11]. Other stud-
ies included patients who were treated between 1980 and 
2000 [9]; during this period, chemotherapy for metastatic 
colorectal cancer (mCRC) changed from 5-fluorouracil-
based two-agent regimens to oxaliplatin- or irinotecan-
based three-agent regimens. Similarly, the principles 
underlying the management of metastatic lesions also 
changed during this period. Also, the reliability of com-
paring one study with another is inevitably challenged by 
patient selection bias.
Apart from the ongoing randomized clinical trials, an 
alternative way to resolve the question is to identify a 
method or index for selecting patients who are likely to 
benefit from PPTR. To date, only one study has indicated 
that patients with rectal cancer or with low levels of car-
cinoembryonic antigen (CEA) are likely to benefit from 
PPTR [12]. Accordingly, in the age of modern chemo-
therapy, we investigated the effect of PPTR on the sur-
vival of patients with synchronous mCRC. Additionally, 




We reviewed the database from Sun Yat-sen University 
Cancer Center and selected patients who met the fol-
lowing criteria: (1) between 2005 and 2012, they were 
diagnosed with mCRC at first diagnosis; (2) they had an 
Eastern Cooperative Oncology Group status ≤2; and (3) 
their follow-up information was available. The follow-
ing patients were excluded: (1) those who had evidence 
of intestinal obstruction, enterobiasis, or bleeding at 
the time of first presentation; (2) those who had a sec-
ond primary tumor; and (3) those who had all visible 
tumors removed. Informed consent was obtained from 
Table 1 Summary of studies that evaluated the role of PPTR
PPTR palliative primary tumor resection, OS overall survival, 5-FU 5-fluorouracil, CF cisplatin and 5-fluorouracil, FOLFOX folinic acid 5-fluorouracil and oxaliplatin, 
FOLFIRI folinic acid, 5-fluorouracil, and irinotecan, XELOX xeloda and oxaliplatin









Seo [4] 2001–2008 Oxaliplatin, irinotecan, and 5‑FU Yes 144 22 0.076
No 83 14
Sabine [16] 2003–2004 Irinotecan, oxaliplatin, and  
capecitabine
Yes 258 16.7 <0.001
No 141 11.4
Sabine [16] 2005–2006 Oxaliplatin and capecitabine Yes 289 20.7 <0.001
No 159 13.4
Leyo [17] 1996–1999 Unknown Yes 127 16 <0.001
No 103 9
Ferrand [18] 1997–2001 5‑FU + CF, 5‑FU, or raltitrexed Yes 156 16.3 <0.001
No 60 9.6
Mehdi [19] 1998–2007 FOLFOX, FOLFIRI, XELOX, or 5‑FU Yes 85 30.7 0.031
No 123 21.9
Tebutt [20] 1990–1999 5‑FU, raltitrexed, capecitabine, or 
uracil tegafur
Yes 280 14 0.080
No 82 8.2
Martyn [21] 1999–2006 Unknown Yes 45 11 0.206
No 52 7
Page 3 of 8He et al. Chin J Cancer  (2016) 35:58 
all patients involved in this study, which was approved by 
the ethical committee of Sun Yat-sen University Cancer 
Center.
Detection of CEA
CEA level was evaluated using electrochemilumines-
cence with the Roche Elecsys 2010 Chemistry Analyzer 
(Basel, Switzerland).
Patient follow‑up and statistical analysis
Overall survival (OS) was defined as the time from diag-
nosis to death or the last follow-up; progression-free 
survival (PFS) after first-line chemotherapy was defined 
as the time from the initiation of first-line chemotherapy 
to disease progression or death. The calculation date was 
October 31, 2014.
SPSS version 13.0 software (Statistical Product and 
Service Solutions, Chicago, IL, USA) was used to per-
form statistical analyses. The Kaplan–Meier method was 
used to plot the survival curves, and the differences were 
compared using the log-rank test. Multivariate analysis 
and the Cox proportional hazards model were used to 
determine independent significance. A P value less than 
or equal to 0.05 was considered significant.
Results
Patient characteristics
In our database, we identified 521 mCRC patients with 
synchronous metastases. Of these patients, 87 underwent 
surgery without chemotherapy, 9 did not receive any 
treatment after diagnosis, and 38 were lost to follow-up; 
the remaining 387 patients were included in our analysis 
(Fig. 1). The patients’ clinicopathologic characteristics at 
baseline are listed in Table 2.
Among the 387 patients studied, 109 refused surgery, 
254 underwent PPTR, and 24 underwent an exploratory 
celiotomy. Of the patients who underwent a celiotomy, 
16 had their abdomen closed immediately because peri-
toneal metastases and other organ involvement were 
found; the remaining eight patients underwent a prophy-
lactic enterostomy because of the advanced stage of the 
primary tumor. Both the patients who refused surgery 
and those who underwent an exploratory celiotomy were 
included in the non-PPTR group.
None of the 254 patients who underwent PPTR died 
as a result of surgery. The median interval between 
PPTR and systemic chemotherapy was 24  days (range, 
13–58 days). Of these patients, 221 underwent PPTR fol-
lowed by chemotherapy, and 33 underwent chemother-
apy followed by PPTR. All 133 patients in the non-PPTR 
group accepted palliative chemotherapy, either oxalipl-
atin-based or irinotecan-based.
The effect of PPTR on OS
Patients who underwent PPTR had a significantly 
longer OS than patients who did not (median: 20.8 vs. 
14.8 months, P < 0.001). We also evaluated the prognos-
tic values of all the factors, including age, sex, primary 
tumor location, metastatic site, regimen of first-line 
chemotherapy, and alkaline phosphatase (ALP), lactate 
dehydrogenase (LDH), and CEA levels (Table  2). ALP 
(P < 0.001), LDH (P < 0.001), and CEA (P < 0.001) levels 
were all prognostic factors. As shown in Table 3, a multi-
variate analysis including PPTR as well as ALP, LDH, and 
CEA levels indicated that PPTR (P  =  0.009) and LDH 
level (P = 0.011) were independent prognostic factors.
Next, we studied the distribution of clinicopathologic 
characteristics at baseline in the PPTR group and non-
PPTR group patients (Table  2). Elevated LDH level was 
observed in 51.1% (68 of 133) of patients in the non-
PPTR group, but only 24.4% (62 of 254) of patients in the 
PPTR group had high LDH level (P  <  0.001). The other 
factors, including age, sex, primary tumor location, meta-
static site, regimen of first-line chemotherapy, and ALP 
and CEA levels, were similar between the two groups.
The effect of PPTR followed by first‑line chemotherapy 
on PFS
The median PFS after first-line chemotherapy of patients 
in the PPTR and non-PPTR groups were 7.3 and 
4.8 months, respectively (P < 0.001). Among the factors 
listed in Table 2, ALP (P < 0.001), LDH (P < 0.001), and 
CEA (P  <  0.001) levels could all be used to distinguish 
patients with different PFS after the first-line chemo-
therapy. A multivariate analysis including PPTR and ALP, 
Included in this study (n = 387)
Excluded (n = 134)
Decline chemotherapy (n = 87)
No treatment aer diagnosis (n = 9)
Lost to follow-up (n = 38)
Assessed for eligibility (n = 521)
PPTR group:
paents with primary 
tumor resecon (n = 254)
Non-PPTR group:
paents without primary 
tumor resecon (n = 133)
Fig. 1 Flow chart of the inclusion of patients with metastatic colorec‑
tal cancer. PPTR palliative primary tumor resection
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LDH, and CEA levels indicated that PPTR (P  =  0.014) 
and LDH level (P = 0.036) were independent factors.
The effect of PPTR on first‑line chemotherapy failure
In this study, all patients accepted first-line chemotherapy; 
each of them accepted at least four cycles of chemother-
apy. We classified the patients into two groups according 
to the nature of first-line chemotherapy failure. If new 
organs were involved in the progression, it was defined 
as systematic progression; if only the primary tumor was 
enlarged or new lesions were emerged only in organs that 
had already been involved, it was defined as local progres-
sion. We found local progression in a larger proportion 
of PPTR group patients compared with non-PPTR group 
patients (86.2% [219/254] vs. 71.4% [95/133], P < 0.001).
LDH and CEA levels could identify patients who may 
benefit from PPTR
Since LDH distribution was not balanced between the 
PPTR and non-PPTR groups, we classified and analyzed 
patient survival according to LDH level. Normal LDH 
level was observed in 257 patients; of these patients, 192 
underwent PPTR, and 65 did not. The OS of the PPTR 
group and non-PPTR group patients with normal LDH 
level was 22.4 and 15.6 months, respectively (P < 0.001). 
The PFS after first-line chemotherapy of the PPTR group 
and non-PPTR group patients who had normal LDH 
levels was 7.8  and 5.5  months, respectively (P  <  0.001). 
Other factors were similar between the two groups, as 
shown in Table  4. Elevated LDH level was observed in 
130 patients; of these patients, 62 accepted PPTR, and 
68 did not. The OS of the PPTR group and non-PPTR 
group patients with elevated LDH level was 18.9  and 
12.9 months, respectively (P = 0.268). The PFS after first-
line chemotherapy of the PPTR group and non-PPTR 
group patients with elevated LDH level was 5.6  and 
4.7 months, respectively (P = 0.100).
Since a wide range in the degree of LDH elevation was 
observed, we divided the patients with increased LDH 
levels into two groups (upper and lower halves) according 
to the degree of elevation to identify patients who could 
potentially benefit from PPTR. As shown in Table 5, we 
found that neither group benefited from PPTR.
Table 2 Characteristics of the 387 colorectal cancer patients with unresectable metastasis
All values are presented as number of patients
PPTR palliative primary tumor resection, CEA carcinoembryonic antigen, ALP alkaline phosphatase, LDH lactate dehydrogenase
Characteristic Variable Total PPTR group Non‑PPTR group P
Age (years) ≤60 210 135 75 0.543
>60 177 119 58
Sex Men 259 169 90 0.822
Women 128 85 43
Location Right 132 87 45 0.120
Left 124 89 35
Rectal 131 78 53
First‑line chemotherapy Oxaliplatin‑based 335 221 114 0.723
Irinotecan‑based 52 33 19
Metastasis organs 1 283 194 89 0.108
2 92 52 40
≥3 12 8 4
CEA (ng/mL) ≤5 81 52 29 0.760
>5 306 202 104
ALP (U/L) ≤110 315 207 108 0.944
>110 72 47 25
LDH (U/L) ≤245 257 192 65 <0.001
>245 130 62 68
Table 3 Multivariate analysis of  prognostic factors in  387 
patients with metastatic colorectal cancer
PPTR palliative primary tumor resection, CEA carcinoembryonic antigen, ALP 
alkaline phosphatase, LDH lactate dehydrogenase, CI confidence interval
Variable B P Exp(B) 95% CI for exp(B)
PPTR −0.452 0.009 0.636 0.453–0.893
ALP −0.210 0.295 0.810 0.546–1.201
LDH −0.453 0.011 0.636 0.450–0.900
CEA −0.161 0.520 0.851 0.522–1.390
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In addition to LDH level, ALP and CEA levels—the 
other significant prognostic factors demonstrated in our 
study—were investigated to determine which patients 
might benefit from PPTR. Normal ALP level was 
observed in 305 patients; of these patients, 221 accepted 
PPTR, and 84 did not. The OS of the PPTR group and 
non-PPTR group patients with normal ALP levels was 
20.9  months (range, 2.8–86.7  months) and 16.3  months 
(range, 3.2–64.5  months), respectively (P  =  0.001). 
Increased ALP levels were observed in 82 patients; of 
these patients, 33 accepted PPTR, and 49 did not. The 
OS of the PPTR group and non-PPTR group patients 
with elevated ALP levels was 19.5  months (range, 4.7–
34.9 months) and 11.3 months (range, 2.3–42.3 months), 
respectively (P  =  0.035). Because patients with both 
increased ALP levels and normal ALP levels could benefit 
from PPTR, ALP was not a predictor of survival benefit. 
Previous studies have suggested that patients with CEA 
levels >600 ng/mL did not benefit from PPTR [12]. In our 
study, 32 patients had CEA levels >600 ng/mL. Of these 
patients, 11 accepted PPTR, and 21 did not. The OS of 
the PPTR group and non-PPTR group patients with 
CEA levels  >600  ng/mL was 17.1  months (range, 8.4–
26.0 months) and 12.9 months (range, 7.2–29.8 months), 
respectively (P = 0.582). However, since only 8.3% (32 of 
387) of the patients had CEA levels >600 ng/mL, the clin-
ical significance is limited. We divided the patients with 
increased CEA levels into three groups: patients in the 
upper third were classified into group A, patients in the 
middle third were classified into group B, and patients 
in the lower third were classified into group C; patients 
with normal CEA levels were classified into group D. As 
shown in Table 6, we found that patients did not benefit 
from PPTR if they had CEA levels >70 ng/mL.
Since both LDH and CEA levels showed the poten-
tial to be used for selecting patients who could benefit 
from PPTR, we investigated whether a combination of 
the two indexes could provide a better predictive model. 
We classified the patients into three groups. Group 1 
consisted of patients who had normal LDH levels and 
CEA levels  ≤70  ng/mL; group 2 consisted of patients 
with increased LDH levels and CEA levels  ≤70  ng/
mL, or patients with normal LDH levels and CEA lev-
els  >70  ng/mL; and group 3 consisted of patients who 
had increased LDH levels and CEA levels  >70  ng/mL. 
As shown in Fig.  2, the OS of groups 1, 2, and 3 were 
20.8  months (range, 2.8–86.7  months), 17.4  months 
Table 4 Characteristics of the 257 colorectal cancer patients with unresectable metastasis who had normal LDH levels
All values are presented as number of patients
PPTR palliative primary tumor resection, CEA carcinoembryonic antigen, ALP alkaline phosphatase, LDH lactate dehydrogenase
Characteristic Variable Total PPTR group Non‑PPTR group P
Age (years) ≤60 141 103 38 0.500
>60 116 89 27
Sex Men 180 134 46 0.882
Women 77 58 19
Location Right 98 75 23 0.799
Left 80 60 20
Rectal 79 57 22
First‑line chemotherapy Oxaliplatin‑based 228 171 57 0.763
Irinotecan‑based 29 21 8
Metastasis organs 1 201 152 49 0.733
2 51 36 15
≥3 5 4 1
CEA (ng/mL) ≤5 62 45 17 0.658
>5 195 147 48
ALP (U/L) ≤110 223 166 57 0.800
>110 34 26 8
Table 5 Overall survival of  the patients grouped by  LDH 
levels
Each value is presented as median followed by range in parentheses
The overall survival was compared between PPTR and non-PPTR group, and the 
differences were analyzed using the log-rank test
LDH lactate dehydrogenase, PPTR palliative primary tumor resection
LDH level (U/mL) Overall survival (months) P
PPTR group Non‑PPTR group
≤245 22.43 (4.07–86.73) 15.63 (2.80–64.50) <0.001
246–380 19.50 (4.70–65.37) 12.23 (2.33–44.43) 0.243
>380 16.83 (2.77–73.20) 15.37 (3.23–41.33) 0.892
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(range, 2.3–73.3  months) and 15.7  months (range, 3.5–
44.4 months), respectively (P < 0.001). We also compared 
the OS of the PPTR group and non-PPTR group patients 
in each group. As shown in Table  7, PPTR patients in 
group 1 had a significantly longer OS than non-PPTR 
patients in group 1 (22.2 vs. 16.2 months, P < 0.001).
Discussion
In the present study, we analyzed the role of PPTR from 
the following aspects: its effect on intestinal complica-
tions, its effect on patient survival, and its safety. We 
found that only patients with normal LDH levels and 
CEA levels  <70  ng/mL gained survival benefits from 
PPTR.
The first potential advantage of PPTR is to reduce 
the incidence of potential intestinal complications dur-
ing chemotherapy. However, the incidence of death and 
major complications, including those associated with 
surgical intervention, was reported to be 14% among 
patients treated with folinic acid (or leucovorin), 5-fluo-
rouracil, and oxaliplatin, a combination better known as 
FOLFOX6, plus bevacizumab [13]. Reports from Memo-
rial Sloan Kettering Cancer Center [14] and Fox Chase 
Cancer Center [15] showed that only 7% and 9.8% of 
patients, respectively, needed surgical intervention for 
intestinal complications experienced during chemother-
apy. Furthermore, a meta-analysis that included seven 
studies involving 850 patients showed that the incidences 
of intestinal obstruction and hemorrhage were 13.9% and 
3.0%, respectively [1]. Thus, these data suggest that pro-
phylactic primary cancer resection before chemotherapy 
is not necessary.
The second indication for PPTR is that it may extend 
patient survival. However, these survival benefits are 
controversial, and previous studies have had several 
drawbacks, including unknown or outdated chemother-
apy regimens and patient selection biases. The patients 
in our study were diagnosed after 2005 and were given 
either the standard mFOLFOX6 regimen (folinic acid, 
5-fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, 
5-fluorouracil, and irinotecan) as first-line chemotherapy. 
Efforts were also made to limit patient selection bias. 
First, we compared the age distribution, performance 
status score, tumor location, and metastasis site between 
the PPTR and non-PPTR groups. Second, the distribu-
tion of the potential prognostic factors, including ALP, 
LDH, and CEA levels, was also compared. All the men-
tioned indexes except LDH levels were balanced between 
the two groups. We found that PFS after first-line 
chemotherapy was significantly extended in the PPTR 
group, which could be important in understanding the 
Table 6 Overall survival of  the patients with  colorectal 
cancer grouped by CEA levels
Each value is presented as median followed by range in parentheses
The overall survival was compared between PPTR and non-PPTR group, and the 
differences were analyzed using the log-rank test
CEA carcinoembryonic antigen, PPTR palliative primary tumor resection
CEA level (ng/mL) Overall survival (months) P
PPTR group Non‑PPTR group
0–5 26.13 (2.80–86.73) 16.83 (2.80–64.50) 0.032
5.1–18 20.90 (2.77–70.30) 14.80 (5.73–41.33) 0.011
18.1–70 19.70 (2.87–63.17) 11.85 (2.33–36.63) 0.002
>70 19.57 (4.70–73.33) 14.17 (3.47–44.43) 0.186
Fig. 2 Overall survival of 387 patients with metastatic colorectal can‑
cer grouped by lactate dehydrogenase (LDH) and carcinoembryonic 
antigen (CEA) levels. Group 1 patients who had normal LDH levels and 
CEA levels ≤70 ng/mL; group 2 patients with increased LDH levels 
and CEA levels ≤70 ng/mL, or patients with normal LDH levels and 
CEA levels >70 ng/mL; group 3 patients who had increased LDH levels 
and CEA levels >70 ng/mL
Table 7 Overall survival of  the patients grouped by  the 
combination of LDH and CEA levels
Each value is presented as median followed by range in parentheses
Group 1 consisted of patients who had normal LDH levels and CEA 
levels ≤70 ng/mL, group 2 consisted of patients with increased LDH levels 
and CEA levels ≤ 70 ng/mL, or patients with normal LDH levels and CEA 
levels >70 ng/mL, group 3 consisted of patients who had increased LDH levels 
and CEA levels >70 ng/mL. The overall survival was compared between PPTR 
and non-PPTR group, and the differences were analyzed using the log-rank test
PPTR palliative primary tumor resection, CEA carcinoembryonic antigen,  
LDH lactate dehydrogenase
Group PPTR group Non‑PPTR group P
Group 1 22.23 (4.07–86.73) 16.23 (2.80–64.50) <0.001
Group 2 20.13 (2.77–73.33) 13.17 (2.33–41.33) 0.188
Group 3 18.50 (4.70–25.50) 13.55 (3.47–44.43) 0.918
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advantage of PPTR; we do not think that patient selection 
bias influenced this PFS. In addition, chemotherapy dis-
continuation did not occur in our study, which suggests 
that patients in both groups tolerated chemotherapy well. 
However, the mechanism of how PPTR can extend PFS 
remains unclear.
Although the indications for PPTR are not established, 
short life expectancy, terminal stage, and poor general 
patient condition are usually considered contraindi-
cations for surgery. To determine which patients can 
benefit from PPTR, we investigated whether the three 
prognostic factors found in our study—ALP, LDH, and 
CEA levels—could identify these patient populations. 
First, we found that only patients with normal LDH 
could get survival benefit from PPTR. We further clas-
sified patients with elevated LDH levels into the upper 
and lower halves and confirmed that neither benefited 
from PPTR. A one-pool analysis reported at the Ameri-
can Society of Clinical Oncology annual meeting in 2012 
indicated that patients with low CEA levels can benefit 
from PPTR [12], but the benefit was lost once CEA lev-
els increased to greater than 600 ng/mL. We found simi-
lar results; however, the cutoff of CEA level in our study 
was 70 ng/mL. Finally, the combination of LDH and CEA 
levels was a better predictor of patient benefit than either 
LDH or CEA levels alone. This superiority was reflected 
in three aspects. The first aspect is that the combination 
of the two indexes can be used to select patients in the 
normal LDH group with relatively poor prognosis and 
patients in the elevated LDH group with relatively good 
prognosis; both of these were defined as moderate-risk 
groups, as shown in Fig.  1. The second aspect is that 
patients in the moderate-risk groups do not benefit from 
PPTR. The third and most important aspect is that only 
patients with a very good prognosis, as opposed to those 
with a moderate or poor prognosis, benefit from PPTR.
The safety of PPTR was another unresolved question. 
No surgery-related deaths were found in our study. The 
average interval between chemotherapy and surgery was 
24 days, which is very similar to the 3-week interval usu-
ally required for adjuvant chemotherapy. However, a 
recent meta-analysis found 2.7% of postoperative mortality 
rate and 11.8% of overall serious complications [1], indicat-
ing that PPTR should only be undertaken with caution.
Our study had several limitations. First, the retrospective 
nature limited its power. Second, we did not further divide 
LDH into subtypes, such as LDH-1 and LDH-5. Third, 
some elderly patients might have had cardiovascular dis-
ease, which could also affect LDH levels. Further prospec-
tive studies are needed to validate the results of our study.
Although the distributions of CEA were balanced 
between the PPTR group and non-PPTR group, it is 
noteworthy that there were significant metastatic organ 
differences between the PPTR and non-PPTR groups 
in our study. The unbalanced distribution of metastasis 
organs may reflect the fact that patients with a smaller 
tumor burden are more likely to implement PPTR in 
clinical practice. We acknowledge that this is a poten-
tial weakness of our study. We think that close attention 
should be paid to tumor burden and metastasis organs 
when future investigations are designed.
In conclusion, we found that PPTR could extend OS 
and PFS after first-line chemotherapy and decrease the 
incidence of new organ involvement in patients with 
mCRC who had unresectable metastases. Although no 
serious surgery-related complications occurred, PPTR 
should be recommended only for patients with normal 
LDH levels and CEA levels <70 ng/mL. However, further 
validation studies are needed.
Authors’ contributions
WZH, YMR, and LPX designed the study. CJ, YMR, FXL, CXY, XYC, and GFG col‑
lected the data. HJQ, XXC, and BZ analyzed the data. WZH, CJ, and LPX wrote 
the manuscript. All authors read and approved the final manuscript.
Author details
1 State Key Laboratory of Oncology in South China, Collaborative Innovation 
Center for Cancer Medicine, Sun Yat‑sen University Cancer Center, Guang‑
zhou 510060, Guangdong, P. R. China. 2 VIP Region, Sun Yat‑sen University 
Cancer Center, Guangzhou 510060, Guangdong, P. R. China. 
Acknowledgements
This work was supported by grants from the Natural Science Foundation of 
Guangdong, China (2015A030313010), Science and Technology Program of 
Guangzhou, China (1563000305) and National Natural Science Foundation of 
China (81272641 and 81572409).
Competing interests
The authors declare that they have no competing interests.
Consent to publish
The patients involved in this study provided consent for publication.
Received: 23 June 2015   Accepted: 15 June 2016
References
 1. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients 
with asymptomatic colorectal cancer and synchronous irresectable 
metastases. Ann Oncol. 2008;19(11):1829–35. doi:10.1093/annonc/
mdn398mdn398.
 2. Zhou Q, Li K, Lin GZ, Shen JC, Dong H, Gu YT, et al. Incidence trends and 
age distribution of colorectal cancer by subsite in Guangzhou, 2000–
2011. Chin J Cancer. 2015;34:34. doi:10.1186/s40880‑015‑0026‑610.1186/
s40880‑015‑0026‑6.
 3. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O’Riordain DS. 
Non‑operative management of the primary tumour in patients with 
incurable stage IV colorectal cancer. Br J Surg. 2001;88(10):1352–6. 
doi:10.1046/j.0007‑1323.2001.01915.x.
 4. Seo GJ, Park JW, Yoo SB, Kim SY, Choi HS, Chang HJ, et al. Intestinal 
complications after palliative treatment for asymptomatic patients with 
unresectable stage IV colorectal cancer. J Surg Oncol. 2010;102(1):94–9. 
doi:10.1002/jso.21577.
 5. Ahmed S, Leis A, Fields A, Chandra‑Kanthan S, Haider K, Alvi R, et al. Sur‑
vival impact of surgical resection of primary tumor in patients with stage 
Page 8 of 8He et al. Chin J Cancer  (2016) 35:58 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
IV colorectal cancer: results from a large population‑based cohort study. 
Cancer. 2014;120(5):683–91. doi:10.1002/cncr.28464.
 6. Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, et al. 
Primary tumour resection and survival in the palliative management 
of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35(2):164–7. 
doi:10.1016/j.ejso.2008.06.
 7. Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients 
presenting with metastatic colorectal cancer: analysis of a provincial 
population‑based cohort. Am J Clin Oncol. 2010;33(1):52–5. doi:10.1097/
COC.0b013e31819e902d.
 8. Gonsalves WI, Wolpert J, Tashi T, Ganti AK, Subbiah S, Ternent C, et al. 
Assessment of prognostic factors after primary tumor resection in 
metastatic colon cancer patients: a Veteran’s Affairs Central Cancer 
Registry (VACCR) analysis, 1995–2008. J Surg Oncol. 2012;106(4):486–90. 
doi:10.1002/jso.23102.
 9. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors 
in patients who present with stage IV colorectal cancer: an analysis of 
surveillance, epidemiology, and end results data, 1988–2000. Ann Surg 
Oncol. 2005;12(8):637–45. doi:10.1245/ASO.2005.06.012.
 10. Kaufman MS, Radhakrishnan N, Roy R, Gecelter G, Tsang J, Thomas 
A, et al. Influence of palliative surgical resection on overall sur‑
vival in patients with advanced colorectal cancer: a retrospec‑
tive single institutional study. Colorectal Dis. 2008;10(5):498–502. 
doi:10.1111/j.1463‑1318.2007.01384.x.
 11. Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, et al. Colo‑
rectal cancer with non‑resectable synchronous metastases: should the 
primary tumor be resected? Gastroenterol Clin Biol. 2004;28(5):434–7.
 12. Faron M, Pignon JP, Bouche O, Douillard JY, Adenis A, Elias D, Ducreux 
M. Impact on survival of primary tumor resection in patients with 
colorectal cancer and unresectable metastasis: pooled analysis of 
individual patients’ data from four randomized trials. J Clin Oncol. 
2012; suppl(30): 3507. http://meeting.ascopubs.org/cgi/content/
abstract/34/4_suppl/704?sid=520abd27‑681f‑482c‑bc25‑b580007b9d54
 13. McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, et al. Primary 
mFOLFOX6 plus bevacizumab without resection of the primary tumor for 
patients presenting with surgically unresectable metastatic colon cancer 
and an intact asymptomatic colon cancer: definitive analysis of NSABP 
trial C‑10. J Clin Oncol. 2012;30(26):3223–8. doi:10.1200/JCO.2012.42.4044.
 14. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. 
Outcome of primary tumor in patients with synchronous stage IV 
colorectal cancer receiving combination chemotherapy without surgery 
as initial treatment. J Clin Oncol. 2009;27(20):3379–84. doi:10.1200/
JCO.2008.20.9817.
 15. Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, et al. 
Outcome and natural history of patients with stage IV colorectal cancer 
receiving chemotherapy without primary tumor resection. Ann Surg 
Oncol. 2012;19(2):379–83. doi:10.1245/s10434‑011‑2028‑1.
 16. Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sin‑
nige HA, et al. Prognostic value of resection of primary tumor in patients 
with stage IV colorectal cancer: retrospective analysis of two randomized 
studies and a review of the literature. Ann Surg Oncol. 2011;18(12):3252–
60. doi:10.1245/s10434‑011‑1951‑5.
 17. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective 
bowel resection for incurable stage IV colorectal cancer: prognostic 
variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722–8. 
doi:10.1016/S1072‑7515(03)00136‑4.
 18. Ferrand F, Malka D, Bourredjem A, Allonier C, Bouche O, Louafi S, et al. 
Impact of primary tumour resection on survival of patients with colorec‑
tal cancer and synchronous metastases treated by chemotherapy: results 
from the multicenter, randomised trial Federation Francophone de 
Cancerologie Digestive 9601. Eur J Cancer. 2013;49(1):90–7. doi:10.1016/j.
ejca.2012.07.006.
 19. Karoui M, Roudot‑Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, 
et al. Primary colectomy in patients with stage IV colon cancer and 
unresectable distant metastases improves overall survival: results of a 
multicentric study. Dis Colon Rectum. 2011;54(8):930–8. doi:10.1097/
DCR.0b013e31821cced0.
 20. Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, et al. 
Intestinal complications after chemotherapy for patients with unre‑
sected primary colorectal cancer and synchronous metastases. Gut. 
2003;52(4):568–73.
 21. Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of 
resection and non‑resection strategies in management of patients 
with advanced colorectal cancer. World J Surg Oncol. 2009;7:28. 
doi:10.1186/1477‑7819‑7‑281477‑7819‑7‑28.
